Please login to the form below

Not currently logged in
Email:
Password:

ADA

This page shows the latest ADA news and features for those working in and with pharma, biotech and healthcare.

Green Valley’s algae-based Alzheimer’s drug to undergo global clinical trials

Green Valley’s algae-based Alzheimer’s drug to undergo global clinical trials

a statistically-significant improvement over placebo on the ADAS-Cog 12 scales used to test cognitive function. ... The mean difference between GV-971 versus placebo in ADAS-Cog12 score at the end of the study was 2.54.

Latest news

More from news
Approximately 17 fully matching, plus 47 partially matching documents found.

Latest Intelligence

  • Assessing the risks in annuity pricing models Assessing the risks in annuity pricing models

    GlaxoSmithKline (GSK) launched its gene therapy STRIMVELIS, a one dose treatment for severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), in Europe in 2016 with an outcomes-based annuity

  • The fight for affordable insulin The fight for affordable insulin

    The movement is also distancing itself from some of the big type 1 diabetes advocacy organisations, such as the American Diabetes Association (ADA) and the Juvenile Diabetes Foundation (JDF), which it

  • 25 Women Leaders in UK Healthcare 25 Women Leaders in UK Healthcare

    Ada is an artificial intelligence (AI) app that helps patients navigate quickly and accurately to the right health service and, ultimately, the right diagnosis. ... So far, Ada has performed eight million assessments around the globe, and every three

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    GSK’s Strimvelis for ADA-SCID (Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency) followed in 2016, and was a similar commercial failure.

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    pancreatitis. Then GSK’s Strimvelis followed in 2016 for a very rare disease called ADA-SCID (Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency).

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Weekly industry appointments Weekly industry appointments

    There, he is medicines development leader for adenosine deaminase deficiency (ADA-SCID) gene therapy Strimvelis – the first alternative medicine to stem cell transplant for the disease that’s bagged a regulatory

  • Orchard Therapeutics appoints Mark Rothera as CEO Orchard Therapeutics appoints Mark Rothera as CEO

    The clinical data we’ve seen to date with Orchard’s therapy for ADA-SCID is exceptional, and the company has assembled and impressive R&D pipeline to apply the approach

  • Cello Health boosts senior leadership team Cello Health boosts senior leadership team

    He previously served as managing director at Medicom International, an international healthcare publishing firm as well as ADA holdings and ICI Pharmaceuticals.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics